Gilead's Trodelvy Wins FDA Nod for Expanded Use in Breast Cancer

Gilead Sciences (GILD) has secured FDA approval to expand the use of its antibody-drug conjugate Trodelvy to include first-line treatment of metastatic triple-negative breast cancer (mTNBC). This opens a broader treatment opportunity for patients who have not received prior therapy.

The Product

Trodelvy is an antibody-drug conjugate that targets Trop-2, a protein expressed on cancer cells, delivering a chemotherapy agent directly. Clinical trials demonstrated significant improvements in progression-free survival and overall survival compared to standard chemotherapy.

Pricing and Availability

Gilead has not disclosed pricing details yet, but it is expected to be in line with similar targeted therapies. The drug will be immediately available in the U.S.

Competition

Trodelvy faces competition from Keytruda (Merck) and Tecentriq (Roche) in the mTNBC space. However, being the first Trop-2-directed therapy approved in the first-line setting may give it a competitive edge.

Potential Impact on Gilead

The expanded indication is expected to significantly boost Trodelvy sales, previously limited to later-line use. Analysts estimate peak annual sales could reach $2-3 billion, supporting Gilead's oncology growth.